Lodovica Zullo

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

Journal: Cancers

Published: July 06, 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 24, 2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 17, 2026

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 02, 2026

Antibody-Drug Conjugates in Non-small Cell Lung Cancer.

Antibody-Drug Conjugates in Non-small Cell Lung Cancer.

Journal: Drugs

Published: January 15, 2026

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

Journal: ESMO open

Published: August 26, 2025

Next-generation multicenter studies: using artificial intelligence to automatically process unstructured health records of patients with lung cancer across multiple institutions.

Next-generation multicenter studies: using artificial intelligence to automatically process unstructured health records of patients with lung cancer across multiple institutions.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 23, 2025

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 22, 2025

Lung metastases.

Lung metastases.

Journal: Nature reviews. Disease primers

Published: July 16, 2025

Single-step genomic evaluation for production and type traits in the Italian Mediterranean Buffalo.

Single-step genomic evaluation for production and type traits in the Italian Mediterranean Buffalo.

Journal: Journal of dairy science

Published: June 14, 2025

Single-step genomic evaluation for production and type traits in the Italian Mediterranean buffalo.

Single-step genomic evaluation for production and type traits in the Italian Mediterranean buffalo.

Journal: Journal of dairy science

Published: June 14, 2025

Showing 1-12 of 43

Last Updated: 09/26/2026